A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform

Recent treatments of leukemias with chimeric antigen receptor (CAR) expressing T cells underline their impressive therapeutic potential. However, once adoptively transferred into patients, there is little scope left to shut them down after elimination of tumor cells or in case adverse side effects o...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncoimmunology
Autores principales: Albert, Susann, Arndt, Claudia, Feldmann, Anja, Bergmann, Ralf, Bachmann, Dominik, Koristka, Stefanie, Ludwig, Florian, Ziller-Walter, Pauline, Kegler, Alexandra, Gärtner, Sebastian, Schmitz, Marc, Ehninger, Armin, Cartellieri, Marc, Ehninger, Gerhard, Pietzsch, Hans-Jürgen, Pietzsch, Jens, Steinbach, Jörg, Bachmann, Michael
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2017
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5414885/
https://ncbi.nlm.nih.gov/pubmed/28507794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1287246
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares